Subscribe To
Ardelyx (ardx) up on fda nod to xphozah for hyperphosphatemia
Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The st...
October 19, 2023, 12:02 pm
Why ardelyx stock popped today
Late yesterday, Ardelyx announced that the FDA has approved its first-in-class chronic kidney disease drug Xphozah. The drug adds an important new tre...
October 18, 2023, 4:31 pm
Ardelyx to present data updates for xphozah (tenapanor) for hyperphosphatemia at kidney week 2023 november 1-5 in philadelphia, pa
WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develo...
October 13, 2023, 8:00 am
Rising sun over ardelyx: a tenapanor tale (rating upgrade)
Ardelyx shows strong financial health, underpinned by 61% QoQ growth in flagship product Ibsrela and an 18-month cash runway. Japanese approval of ten...
October 9, 2023, 8:55 am
Ardelyx presents positive data further supporting efficacy and safety of xphozah® (tenapanor) at national kidney foundation 2023 spring clinical meetings
Three posters support the important role that XPHOZAH, a novel phosphate absorption inhibitor, could potentially play in the treatment of ...
April 12, 2023, 8:05 pm
The hyperphosphatemia market is expected to reach us$ 20.44 billion and to expand at a cagr of 4.8% through 2033 | future market insights, inc.
Treatment for hyperphosphatemia to Generate a Value Pool exceeding US$ 20 Billion by 2033; Iron-based P...
January 11, 2023, 12:30 am
Ardelyx: the journey continues
Shares of biopharmaceutical concern Ardelyx, Inc. have fallen over 60% since the FDA initially rejected its hy...
December 29, 2022, 4:01 pm
Unicycive to participate in upcoming investor conferences
Highlights Late-Stage Program in hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitoch...
November 28, 2022, 7:00 am